drugset

drugset / Trial / NCT01921257

Paediatric Safety Study in Cat-PAD

NCT01921257 ↗

Phase 2 Completed 16 enrolled Circassia Limited inVentiv Health Clinical · collab

Non-randomizedSingle-groupSingle-blindTreatment

Summary

Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects

Timeline

Start: 2013-08
Primary completion: 2015-12
Completion: 2015-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cat-PAD	Peptide	—	—

Indications